Adoptive transfer of gene modified T cells provides possible
immunotherapy for patients with
cancers refractory to other treatments. We have previously used the non-viral piggyBac transposon system to gene modify human T cells for potential
immunotherapy. However, these previous studies utilized adoptive transfer of modified human T cells to target
cancer xenografts in highly immunodeficient (NOD-SCID) mice that do not recapitulate an intact immune system. Currently, only viral vectors have shown efficacy in permanently gene-modifying mouse T cells for
immunotherapy applications. Therefore, we sought to determine if piggyBac could effectively gene modify mouse T cells to target
cancer cells in a mouse
cancer model. We first demonstrated that we could gene modify cells to express murine
interleukin-12 (p35/p40
mIL-12), a transgene with proven efficacy in
melanoma immunotherapy. The OT-I
melanoma mouse model provides a well-established T cell mediated immune response to
ovalbumin (OVA) positive
B16 melanoma cells. B16/OVA
melanoma cells were implanted in wild type C57Bl6 mice. Mouse splenocytes were isolated from C57Bl6 OT-I mice and were gene modified using piggyBac to express
luciferase. Adoptive transfer of
luciferase-modified OT-I splenocytes demonstrated homing to B16/OVA
melanoma tumors in vivo. We next gene-modified OT-I cells to express mIL-12. Adoptive transfer of mIL-12-modified mouse OT-I splenocytes delayed B16/OVA
melanoma tumor growth in vivo compared to control OT-I splenocytes and improved mouse survival. Our results demonstrate that the piggyBac transposon system can be used to gene modify splenocytes and mouse T cells for evaluating adoptive immunotherapy strategies in immunocompetent mouse
tumor models that may more directly mimic
immunotherapy applications in humans.